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The first randomised trials designed to test the effect of plasma cholesterol reduction came out in the mid-sixties and were largely carried out on patients who already had coronary heart disease. The trials were small and had relatively few new incidents of coronary heart disease in the treatment groups. Even in these high risk populations no general agreement on the benefit of cholesterol lowering was reached, and there was even the suggestion of an excess of non-cardiac related deaths in the treated groups. The first meta-analysis of randomised trials of cholesterol lowering, however, found no indication of an excess of cancer or total mortality in the groups treated by diet.' Discussion about the value of lowering plasma lipid concentrations has continued, boosted by the finding of an excess total mortality in the treated group of the WHO clofibrate trial2 and the findings from the four multifactorial trials (MRFIT,3 WHO factory study,4 the Finnish Miettinen study,5 and the Primary Prevention Study in Gothenburg6 that failed to show a reduction in all cause or coronary heart disease mortality. In fact, of the multifactorial trials only the Oslo diet and anti-smoking trial showed a beneficial effect of this combined intervention advice in high risk healthy men. 7 The debate8 9 about the advantages of plasma lipid lowering has continued world-wide and it is apparent that many trials have achieved a striking reduction in non-fatal coronary heart disease events. 8 The benefit of cholesterol reduction on coronary heart disease mortality, however, was again questioned after the 15 year extended follow up of the Finnish Miettinen study suggested an excess of coronary deaths in the treated group.'0 Net cholesterol reduction has in fact been very modest-that is, about 5% overall in all published randomised trials. The Lipid Research Clinics Primary Prevention trial projected a 10% decrease in overall coronary heart disease risk from such a reduction in cholesterol" and the expected decrease in total mortality, especially in asymptomatic subjects in whom primary prevention is the aim, is even smaller. Thus, much of the controversy about total mortality and cholesterol reduction cannot be resolved, and indeed is the result of a lack of sufficient statistical power in the studies. Properly performed meta-analysis of the published trials can, albeit imperfectly, resolve this under powering.
Meta-analysis: methodological considerations Appropriate meta-analysis should provide results with considerably greater statistical power for important end points and subgroups than single trials. It may also resolve controversies when studies do not accord and give answers to new questions not raised in the single trials. Another benefit is a major improvement in the precision of the estimates of effect size.
Meta-analysis is a statistical method that combines or integrates the results of several independent clinical trials which are considered by the analyst to be combinable.'2 Nevertheless, meta-analysis is not a totally objective science. A set of rigorous criteria for performing the analysis should be established before starting. For example, a protocol should be developed a priori and should cover important issues such as what studies are to be included or excluded. Should a weighted system be used to put more weight on "good" studies than "bad" ones? How do we select and define proper end points and how do we treat the questions of heterogeneity and sensitivity in study outcomes?
The introduction of a weighting system for good or bad trials would require an independent body of information, preferably given by sources other than the analyst. Items such as blindness, placebo control, and size can be graded and put together into a quality score for each trial and used as weights in a quality weighted or adjusted meta-analysis. But there can also be a subjective bias in weighting.
In any meta-analysis a key issue is whether the treatment effects seen in the trials are broadly similar Only mine examined the dose response relation between cholesterol reduction and coronary heart disease incidence or total mortality risk.'8 Two multifactorial trials5 6 were not included in my study. In the analysis Analysis by weighted regression, modified for trial size, is used to analyse the dose response relation between log OR and the net difference in cholesterol. The slope of this regression will estimate the so-called cholesterol benefit ratio-that is, the percentage reduction in risk for each percentage reduction in cholesterol. The Lipid Research Clinics trial estimated that ratio was 2-0% for coronary heart disease. 7 I use multiple weighted regression analysis to investigate whether this benefit ratio is dependent on other design characteristics such as diet or drug, primary or secondary prevention, or single or multifactorial trials.
I present here I include these two trials, and RESULTS OF META-ANALYSIS another recently published trial.'9 Thus I Tables 1 and 2 and fig 1 show the details of include 22 trials for total mortality and 19 for 22 trials.2-7 19-34 For coronary heart disease coronary heart disease incidence.
incidence (n=19) a clear benefit of treatment There is a great variation in design among is observed (OR=0O91, 95% confidence interall cholesterol lowering trials. The trials have val (CI) 087 to 096). For total mortality, open and placebo treated control groups, are however, there was an estimated slight excess of diet and drug treated active groups of pri-risk of treatment (OR= 1 02, 95% CI 097 to mary and secondary prevention and they have 1 07). Table 3 shows that the extent of single and multifactorial designs. Some cholesterol reduction is different in various intervention populations are at high risk and types of trial. Multifactor trials were not others were at normal risk and the trials var-effective in reducing total cholesterol. The ied greatly in duration and size. So any asso-results of primary preventive diet trials were ciation between outcome and a risk factor also poor. that is common to all or most of the studies Table 2 shows that the results in terms of must be an important determinant of the coronary heart disease incidence and total potential for prevention. mortality were heterogeneous.
In the present analysis I use the incidence
To study this heterogeneity in more detail of coronary heart disease (death from coro-the results are presented for groups of trials nary heart disease and confirmed non-fatal (figs 2 and 3). Confidence intervals on the log infarction) and total mortality as the two end OR scale are given for the two end points. points according to the intention to treat Single factor -trials had better effects than principle. I have not considered end points multi-factor trials on coronary heart disease that occurred after ordinary termination of a incidence (p<005) and most of the differstudy, even if such additional results were ence can be explained by difference in cholesreported. Nor have I included angiographic terol reduction between the two subgroups of studies of atherosclerosis. trials. Secondary preventive trials were signifiThe cholesterol response was calculated as cantly better than primary preventive trials the percentage net difference in cholesterol and again the difference can be explained by between treatment groups during the trial the difference in cholesterol reduction. The phase. For all trials combined the weighted more modest difference in coronary heart (by trial size) average of percentage net cho-disease reduction between diet trials and drug lesterol difference was about 4-5%, depend-trials again accords with the more modest ing on the end point analysed.
difference in cholesterol reduction produced by diet.
STATISTICAL METHODS
So before such trial subgroups can be comThe overall estimate of the treatment effect pared adjustments must be made for differwas obtained by averaging the odds ratio ences in cholesterol reduction. Figure 4 (OR) across all the studies.'3 This procedure shows the weighted regression line between also gives a 95% cenfidence interval for the log OR of coronary heart disease incidence average OR. A useful graphical display in this and the percentage reduction in cholesterol context is the Galbraith plot.'3 This method (SE in parentheses). The slope of the line displays each trial as a single point. The (-0 025) indicates that for each 1% reducvertical axis is the standard log OR and the tion in cholesterol an associated 2-5% reduchorizontal axis is a measure of the sample size tion in coronary heart disease incidence is to and thus gives an indication of the precision be expected on the average (cholesterol beneof the log OR estimation. A line is fitted to fit ratio). This result was similar in single facthe points passing through the origin and tor and in multi-factor trials (slope (single) = calculated by least squares. The slope of this -00248; slope (multi) = -0 0272) that is, line gives the pooled OR and parallel lines at irrespective of the average magnitude of cho-± 2SD give the normal variation. One advan-lesterol reduction.
tage of such plots is that heterogeneous Figure 5 shows the dose response relation results are highlighted when points lie outside for total mortality. The slope was -0 75% this range.
for each 1 % reduction in cholesterol. A com- Figure 1 Galbraith plot of log OR (vertical axis) for coronary heart disease incidence with adjustment for trial size (horizontal axis). Small studies lie to the left whereas larger studies to the right will influence the regression line to a greater degree. The parison of the slope of single factor and multi-factor trials shows a tendency to heterogeneity (slope (single) = -0-02 17 and slope (multi) = +00001; NS). Figure 5 shows that it may be possible to draw a line with a positive slope within the given confidence interval; however, the magnitude of positivity can only be small.
The x2 error terms for the models with linear fit give X20 = 27-8 for total mortality (NS) and X7 = 23-2 for coronary heart disease incidence (NS)-that is, there is no significant heterogeneity after allowing for differences in cholesterol reduction. Thus comparisons between single groups of trials are valid once there has been a proper adjustment for cholesterol reduction. Figures 6 and 7 show similar graphs for absolute change in cholesterol (mg/dl). Each 1 mg/dl reduction in cholesterol is associated with 1* I % reduction in coronary heart disease incidence. For total mortality the slope is -0-38%. So a reduction in cholesterol from 7 mmol/l to 6 mmol/l in a population should reduce the incidence of coronary heart disease by about 42% and total mortality by about 12%.
But the cholesterol benefit ratio is also dependent on the baseline cholesterol concentration in a trial. The benefit ratio for coronary heart disease is only about 1-2 when cholesterol is below 5*0 mmol/l at baseline. 
Discussion
The results from single factor and multifactorial trials and from trials of primary and secondary prevention tend to be different. With adjustments for cholesterol reduction, however, this heterogeneity vanishes. The coronary heart disease cholesterol benefit ratio was estimated to be 2-5 when all 19 randomised trials with available information were included. Thus there are two major considerations in trials of the impact of plasma cholesterol reduction: to what degree was plasma cholesterol concentration lowered and what was the statistical power of the study.
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The relation of plasma cholesterol reduc- Figure 6 Relation between log OR for coronary heart disease incidence and absolute change in plasma cholesterol. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis Absolute change in cholesterol (mg/dl) Figure 7 Relation between log odds ratio for total mortality and absolute change in plasma cholesterol. 
